"Pertussis vaccine"

Optimising the timing of whooping cough immunisation in mums (OpTIMUM) through investigating pertussis vaccination in pregnancy: an open-label, equivalence, randomised controlled trial. Pertussis vaccination in pregnancy is recommended in many countries to provide protection to young infants. The best timing for this vaccination is uncertain. In the UK, vaccination is recommended between 16 weeks and 32 weeks of gestation. In this trial we aimed to investigate the equivalence of three time periods for pertussis vaccination in pregnancy. In this open-label, equivalence, randomised controlled trial to investigate equivalence of different time windows for pertussis vaccination in pregnancy, participants were randomly assigned (1:1:1 ratio) to receive a pertussis-containing vaccine (Boostrix

and poster. 3. 8 September 2017 Added new poster for vaccination from 16 weeks. 4. 3 July 2017 Revised to include more detail about the pertussis vaccine and eligibility. 5. 31 October 2016 Revised leaflet and poster supporting the whooping cough vaccination in pregnancy programme. 6. 27 June 2014 Added URLs of 'vaccination against pertussis (whooping cough) for pregnant women programme page' and 'whooping Whooping cough: vaccination in pregnancy programme resources Whooping cough: vaccination in pregnancy programme resources - GOV.UK Cookies on GOV.UKWe use some essential cookies to make this website work. We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services. We also use cookies set by other sites to help us deliver content

Pertussis Immunity 5 Years After Booster Vaccination With Recombinant Pertussis Vaccines. This cohort study compares levels of immunity 5 years after vaccination among adolescents given genetically detoxified pertussis boosters with those given chemically inactivated pertussis boosters.

emails about this page Contents 1. Whooping cough immunisation of health professionals 2. Information for healthcare workers exposed to whooping cough 3. Exposure in a healthcare setting Print this page Whooping cough immunisation of health professionalsImmunisation of health professionals was considered by the Joint Committee on Vaccination and Immunisation (JCVI) as part of a range of control Whooping cough (pertussis): immunisation of healthcare workers Whooping cough (pertussis): immunisation of healthcare workers - GOV.UK Skip to main content Cookies on GOV.UKWe use some essential cookies to make this website work.We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.We also use cookies set by other sites

Methods and analysis of the longterm follow up of the effectiveness of one whole cell and two acellular pertussis vaccines Methods and analysis of the long-term follow up of the effectiveness of one whole cell and two acellular pertussis vaccines Technical report 2 This title can be downloaded from: www.folkhalsomyndigheten.se/publications. You are welcome to cite our texts, but please remember to state the source. Images, photographs and illustrations are protected by copyright. In order to use them, permission must be given by the author. © Public Health Agency of Sweden, Year 2022. Article number: 21289 3 About this publication This long-term follow up is based on the large, blinded randomized infant pertussis vaccination trial that is internationally known as “Stockholm Trial II

Immunogenicity and safety of BPZE1, an intranasal live attenuated pertussis vaccine, versus tetanus-diphtheria-acellular pertussis vaccine: a randomised, double-blind, phase 2b trial. Bordetella pertussis epidemics persist as transmission remains unabated despite high acellular pertussis vaccination rates. BPZE1, a live attenuated intranasal pertussis vaccine, was designed to prevent B pertussis infection and disease. We aimed to assess the immunogenicity and safety of BPZE1 compared with the tetanus-diphtheria-acellular pertussis vaccine (Tdap). In this double-blind, phase 2b trial at three research centres in the USA, healthy adults aged 18-50 years were randomly assigned (2:2:1:1) via a permuted block randomisation schedule to receive BPZE1 vaccination followed by BPZE1 attenuated challenge

Immunogenicity, reactogenicity, and IgE-mediated immune responses of a mixed whole-cell and acellular pertussis vaccine schedule in Australian infants: A randomised, double-blind, noninferiority trial In many countries, infant vaccination with acellular pertussis (aP) vaccines has replaced use of more reactogenic whole-cell pertussis (wP) vaccines. Based on immunological and epidemiological

Promotion and COVID-19 lockdown increase uptake of funded maternal pertussis vaccination in pharmacy: A mixed methods study. Pertussis vaccination is recommended during pregnancy to protect the baby. Pertussis vaccination was initially free to pregnant people through general practice and hospitals in New Zealand, but uptake was suboptimal. In one district funding of maternal pertussis vaccination was widened to community pharmacies in 2016. Eighteen months later promotion to pharmacies, midwives and pregnant people took place. In 2020 and 2021, COVID-19 lockdowns occurred. To explore the effects of promotion and COVID-19 lockdowns on uptake of funded maternal pertussis vaccination in pharmacy, and awareness, use and opinions of promotional elements. Five years of pharmacy claims data

The association of public health interventions regarding both infant sleep position and pertussis immunization with sudden infant death syndrome rates: an ecological study. Infections may play a role in the etiology of sudden infant death syndrome (SIDS), with Bordetella pertussis being a potential agent. The objective was to analyze the association of SIDS and infant pertussis hospitalization

What Is the Impact of Maternal Pertussis Immunization in Pregnancy on the Quantity, Quality and Longevity of Infant Vaccine Responses?: A Review of the Current Evidence. Immunizing pregnant women against pertussis has been a powerful tool adopted in many countries to effectively reduce morbidity and mortality from whooping cough in young infants when they are most vulnerable to complications of pertussis vaccination during pregnancy not only on the quantity but also the quality and longevity of the infant's antibody responses to pertussis and non-pertussis-related vaccine antigens in the primary immunization series. We will discuss the underlying mechanisms proposed to explain how maternal antibodies may have a modulating effect, and the existing data across different settings on whether

Infant Responses to Primary Immunization Following Vaccination in Pregnancy With Varying Doses of Recombinant Acellular Pertussis Vaccine Alone or Combined With Tetanus-Diphtheria. Vaccination in pregnancy with recombinant pertussis vaccine results in similar or higher antibody levels in infants compared with chemically detoxified acellular pertussis vaccine (Tdapchem). We evaluated antibody responses to primary childhood vaccination in infants born to mothers vaccinated in pregnancy with recombinant pertussis vaccine containing 1, 2 or 5 µg genetically detoxified pertussis toxin (ap1gen, Tdap1gen, Tdap2gen or TdaP5gen) or Tdapchem. Infants (393) received diphtheria-tetanus-whole cell pertussis (DTwP) at 2, 4 and 6 months (3+0) and 13-valent pneumococcal conjugate vaccine (PCV13) at 2, 4

Pertussis Vaccination During Pregnancy: Regional Situation and Impact of Implementation on National Immunization Programs in Latin America. Infants face a high risk of morbidity and mortality from pertussis early in life, leading to the adoption of maternal vaccination. This study aimed to review the characteristics of the maternal pertussis vaccination in Latin American (LATAM) countries

immunity, and the amount of IgA in breastmilk may impact mucosal immunity. It is important to understand if the timing of vaccination in pregnancy affects the concentration of IgA in breastmilk. Participants recruited as part of the MAMA (Maternal Antibody in Milk After Vaccination) and OpTIMUM (Optimizing the Timing of Whooping Cough Immunisations in Mums) trials received a pertussis-containing vaccine Antibody in Breastmilk Following Pertussis Vaccination in Three-time Windows in Pregnancy. Pertussis-containing vaccines are routinely offered in the UK at 16-32 weeks of gestation and have been shown to be safe and effective, but there remains debate about the best timing for vaccination. Most research into this has focused on serologic immunity, but breastmilk is also important in infant

Safety and immunogenicity of an acellular pertussis vaccine containing genetically detoxified pertussis toxin administered to pregnant women living with and without HIV and their newborns (WoMANPOWER): a randomised controlled trial in Uganda. Immunisation in pregnancy against pertussis can reduce severe disease in infancy. There are few data on the safety and immunogenicity of vaccines given to pregnant women living with HIV and their infants. We aimed to describe the safety and immunogenicity of a tetanus-diphtheria-acellular pertussis (TdaP) vaccine containing genetically detoxified pertussis toxin given to pregnant women living with HIV and the effect of the vaccine on infant whole-cell pertussis vaccine responses. We conducted an observer-blind, randomised, phase 2, multicentre, non

Acellular Pertussis Vaccine Given in the Week After Birth Does Not Impair Antibody Responses to Later Childhood Doses. A birth acellular pertussis vaccine may be a valuable alternative for immunity against infant pertussis when a pregnancy pertussis vaccine has not been administered. We assessed whether a birth dose may impair immunoglobulin G (IgG) responses to childhood pertussis boosters the study period, and all schedules showed good immunogenicity to subsequent boosters. The high-dose DTPa vaccine consistently induced higher antibody titers than the low-dose dTpa vaccine. Either booster dose was able to bridge immunity between 6 months and 4 years. A birth dose of acellular pertussis vaccine does not impair antibody responses to booster doses of pertussis vaccines and may

A Phase 2b Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 6-Valent Group B Streptococcus Vaccine Administered Concomitantly With Tetanus, Diphtheria, and Acellular Pertussis Vaccine in Healthy Nonpregnant Female Individuals. Maternal group B streptococcus (GBS) infection is associated with substantial risk of preterm birth and infant mortality. Preventative approaches

Association between pertussis vaccination in infancy and childhood asthma: A population-based record linkage cohort study. Asthma is among the commonest noncommunicable diseases of childhood and often occurs with other atopic comorbidities. A previous case-control study found evidence that compared to children who received acellular pertussis (aP) vaccines in early infancy, children who received ) and New South Wales (NSW), receiving wP versus aP vaccine as the first pertussis vaccine dose. The main outcome and measures were first and recurrent hospitalizations for asthma; hazard ratios (HRs) and 95% confidence intervals (CIs) were computed by means of Cox and Andersen and Gill models. 274,405 children aged between 5 and < 15 years old (78.4% NSW-born) received a first dose of either wP (67.8

Transplacental transfer of maternal antibodies following immunization with recombinant pertussis vaccines during pregnancy: real-world evidence. This study investigates placental antibody transfer following recombinant pertussis vaccination in pregnancy in a real-world setting. This post-marketing observational study recruited pregnant women vaccinated with monovalent recombinant acellular pertussis vaccine (aP; n=199) or combined to tetanus-diphtheria (TdaP; n=200), or Td-vaccine only (n=54). Pregnancy, delivery, and neonatal outcomes were assessed. Cord blood was collected post-delivery and pertussis toxin (PT)-IgG, filamentous hemagglutinin (FHA)-IgG and PT-neutralizing antibodies (PT-Nab) were assessed. No adverse pregnancy, delivery, or neonatal outcomes attributed to aP TdaPgen or Td

The effectiveness of maternal pertussis vaccination for protecting Aboriginal and Torres Strait Islander infants against infection, 2012-2017: a retrospective cohort study. To evaluate the effectiveness of maternal pertussis vaccination for preventing pertussis infections in Aboriginal and Torres Strait Islander infants under seven months of age. Retrospective cohort study; analysis of linked months of age, and estimated effectiveness of maternal vaccination for protecting infants against pertussis infection, each by Indigenous status. Of the 19 892 Aboriginal and Torres Strait Islander women who gave birth to live infants during 2012-2017, 7398 (37.2%) received pertussis vaccine doses during their pregnancy, as had 137 034 of 259 526 non-Indigenous women (52.8%; Indigenous v non-Indigenous

IL-17 and IFN-γ-producing respiratory tissue resident memory CD4 T cells persist for decades in adults immunized as children with whole cell pertussis vaccines. The objective was to determine if antigen-specific tissue resident memory T (TRM) cells persist in respiratory tissues of adults immunized as children with whole cell pertussis (wP) or acellular pertussis (aP) vaccines. Mononuclear cells